BDTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BDTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-30), Black Diamond Therapeutics's share price is $4.745. Black Diamond Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $1.99. Hence, Black Diamond Therapeutics's Price to Tangible Book Ratio of today is 2.39.
The historical rank and industry rank for Black Diamond Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
During the past 7 years, Black Diamond Therapeutics's highest Price to Tangible Book Ratio was 4.41. The lowest was 0.46. And the median was 1.40.
A closely related ratio is called PB Ratio. As of today, Black Diamond Therapeutics's share price is $4.745. Black Diamond Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $1.99. Hence, Black Diamond Therapeutics's P/B Ratio of today is 2.39.
The historical data trend for Black Diamond Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Black Diamond Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Price-to-Tangible-Book | Get a 7-Day Free Trial | - | 3.76 | 0.99 | 0.57 | 1.24 |
Black Diamond Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 0.70 | 2.24 | 1.10 | 1.24 | 2.55 |
For the Biotechnology subindustry, Black Diamond Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Black Diamond Therapeutics's Price-to-Tangible-Book falls into.
Black Diamond Therapeutics's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Mar. 2024 ) |
= | 4.745 | / | 1.986 | |
= | 2.39 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Black Diamond Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Biotech Growth N V | 10 percent owner | ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
Ra Capital Nexus Fund, L.p. | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ali Behbahani | director, 10 percent owner | 5425 WISCONSIN AVE, CHEVY CHASE MD 20815 |
Peter Kolchinsky | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ra Capital Management, L.p. | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ra Capital Healthcare Fund Lp | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
David M. Epstein | director, officer: See Remarks | OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747 |
Sergey Yurasov | officer: CHIEF MEDICAL OFFICER | C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E., SUITE 310, SEATTLE WA 98102 |
Elizabeth Buck | officer: CHIEF SCIENTIFIC OFFICER | C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142 |
Erika Jones | officer: SEE REMARKS | C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142 |
Fang Ni | officer: SEE REMARKS | C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142 |
Biotech Ag Bb | 10 percent owner | SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200 |
Wendy L Dixon | director | |
Mark A. Velleca | director | 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709 |
Brent Hatzis-schoch | officer: See Remarks | C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451 |
From GuruFocus
By Value_Insider Value_Insider • 12-19-2022
By Marketwired • 11-06-2023
By Value_Insider Value_Insider • 11-08-2022
By PurpleRose PurpleRose • 08-09-2022
By Marketwired • 10-14-2023
By GlobeNewswire • 06-30-2023
By PurpleRose PurpleRose • 07-11-2022
By Value_Insider Value_Insider • 11-09-2022
By PurpleRose PurpleRose • 08-03-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.